BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pollak MN, Schally AV. Mechanisms of antineoplastic action of somatostatin analogs. Proc Soc Exp Biol Med. 1998;217:143-152. [PMID: 9452137 DOI: 10.3181/00379727-217-44216] [Cited by in Crossref: 114] [Cited by in F6Publishing: 112] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Dalm VA, van Hagen PM, van Koetsveld PM, Achilefu S, Houtsmuller AB, Pols DH, van der Lely AJ, Lamberts SW, Hofland LJ. Expression of somatostatin, cortistatin, and somatostatin receptors in human monocytes, macrophages, and dendritic cells. Am J Physiol Endocrinol Metab. 2003;285:E344-E353. [PMID: 12684217 DOI: 10.1152/ajpendo.00048.2003] [Cited by in Crossref: 102] [Cited by in F6Publishing: 101] [Article Influence: 5.7] [Reference Citation Analysis]
2 Zhao Y, Peng L, Li X, Zhang Y. Expression of somatostatin and its receptor 1-5 in endometriotic tissues and cells. Exp Ther Med 2018;16:3777-84. [PMID: 30405748 DOI: 10.3892/etm.2018.6730] [Reference Citation Analysis]
3 Hall GH, Turnbull LW, Richmond I, Helboe L, Atkin SL. Localisation of somatostatin and somatostatin receptors in benign and malignant ovarian tumours. Br J Cancer 2002;87:86-90. [PMID: 12085262 DOI: 10.1038/sj.bjc.6600284] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
4 Wang CH, Zheng WB, Qiang O, Tang CW. Effects of non-cytotoxic drugs on the growth of multidrug-resistance human gastric carcinoma cell line. Journal of Digestive Diseases 2009;10:91-8. [DOI: 10.1111/j.1751-2980.2009.00370.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
5 Gibson S, Strutt R, Chye R. Managing a malignant orocutaneous fistula: stem the tide with octreotide? Intern Med J 2002;32:191-2. [PMID: 11951935 DOI: 10.1046/j.1444-0903.2001.00190.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
6 Valsecchi ME, Coronel M, Intenzo CM, Kim SM, Witkiewicz AK, Sato T. Somatostatin receptor scintigraphy in patients with metastatic uveal melanoma. Melanoma Res. 2013;23:33-39. [PMID: 23164993 DOI: 10.1097/CMR.0b013e32835b70e9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
7 Keller G, Engel JB, Schally AV, Nagy A, Hammann B, Halmos G. Growth inhibition of experimental non-Hodgkin's lymphomas with the targeted cytotoxic somatostatin analogue AN-238. Int J Cancer 2005;114:831-5. [DOI: 10.1002/ijc.20806] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
8 Mishima M, Yano T, Jimbo H, Yano N, Morita Y, Yoshikawa H, Schally AV, Taketani Y. Inhibition of human endometrial cancer cell growth in vitro and in vivo by somatostatin analog RC-160. American Journal of Obstetrics and Gynecology 1999;181:583-90. [DOI: 10.1016/s0002-9378(99)70496-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
9 Massari D, Trobonjač Z, Rukavina D, Radošević-stašić B. SMS 201-995 enhances S-phase block induced by 5-fluorouracil in a human colorectal cancer cell line. Anti-Cancer Drugs 2005;16:989-96. [DOI: 10.1097/01.cad.0000180118.93535.2b] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
10 Gennigens C, Menetrier-Caux C, Droz JP. Insulin-Like Growth Factor (IGF) family and prostate cancer. Crit Rev Oncol Hematol 2006;58:124-45. [PMID: 16387509 DOI: 10.1016/j.critrevonc.2005.10.003] [Cited by in Crossref: 100] [Cited by in F6Publishing: 86] [Article Influence: 6.7] [Reference Citation Analysis]
11 Reynaert H, Rombouts K, Vandermonde A, Urbain D, Kumar U, Bioulac-Sage P, Pinzani M, Rosenbaum J, Geerts A. Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma. Gut. 2004;53:1180-1189. [PMID: 15247189 DOI: 10.1136/gut.2003.036053] [Cited by in Crossref: 73] [Cited by in F6Publishing: 73] [Article Influence: 4.3] [Reference Citation Analysis]
12 Zapata PD, Colas B, López-Ruiz P, Ropero RM, Martín RM, Rodríguez FJ, González FJ, López JI, Angulo JC. [Phosphotyrosine phosphatase SHP-1, somatostatin and prostate cancer]. Actas Urol Esp 2004;28:269-85. [PMID: 15248398 DOI: 10.1016/s0210-4806(04)73075-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
13 Vinik AI, Anthony L, Boudreaux JP, Go VL, O'Dorisio TM, Ruszniewski P, Woltering EA. Neuroendocrine tumors: a critical appraisal of management strategies. Pancreas 2010;39:801-18. [PMID: 20664478 DOI: 10.1097/MPA.0b013e3181ea5839] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
14 Qin RY, Fang RL, Gupta MK, Liu ZR, Wang DY, Chang Q, Chen YB. Alteration of somatostatin receptor subtype 2 gene expression in pancreatic tumor angiogenesis. World J Gastroenterol 2004; 10(1): 132-135 [PMID: 14695784 DOI: 10.3748/wjg.v10.i1.132] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
15 Pozzi G, Guidi M, Laudicina F, Marazzi M, Falcone L, Betti R, Crosti C, Müller EE, Dimattia GE, Locatelli V, Torsello A. IGF-I stimulates proliferation of spontaneously immortalized human keratinocytes (HACAT) by autocrine/paracrine mechanisms. J Endocrinol Invest 2004;27:142-9. [DOI: 10.1007/bf03346259] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
16 Losa M, Ciccarelli E, Mortini P, Barzaghi R, Gaia D, Faccani G, Papotti M, Mangili F, Terreni MR, Camanni F, Giovanelli M. Effects of Octreotide Treatment on the Proliferation and Apoptotic Index of GH-Secreting Pituitary Adenomas. The Journal of Clinical Endocrinology & Metabolism 2001;86:5194-200. [DOI: 10.1210/jcem.86.11.7986] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 1.7] [Reference Citation Analysis]
17 Pyronnet S, Bousquet C, Najib S, Azar R, Laklai H, Susini C. Antitumor effects of somatostatin. Mol Cell Endocrinol. 2008;286:230-237. [PMID: 18359151 DOI: 10.1016/j.mce.2008.02.002] [Cited by in Crossref: 104] [Cited by in F6Publishing: 101] [Article Influence: 8.0] [Reference Citation Analysis]
18 Frühwald MC, O'dorisio MS, Pietsch T, Reubi JC. High Expression of Somatostatin Receptor Subtype 2 (sst2) in Medulloblastoma: Implications for Diagnosis and Therapy. Pediatr Res 1999;45:697-708. [DOI: 10.1203/00006450-199905010-00016] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 1.9] [Reference Citation Analysis]
19 Berardi R, Morgese F, Torniai M, Savini A, Partelli S, Rinaldi S, Caramanti M, Ferrini C, Falconi M, Cascinu S. Medical treatment for gastro-entero-pancreatic neuroendocrine tumours. World J Gastrointest Oncol 2016; 8(4): 389-401 [PMID: 27096034 DOI: 10.4251/wjgo.v8.i4.389] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
20 Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 1998;351:1393-1396. [PMID: 9593409 DOI: 10.1016/s0140-6736(97)10384-1] [Cited by in Crossref: 1181] [Cited by in F6Publishing: 333] [Article Influence: 51.3] [Reference Citation Analysis]
21 Hejna M, Schmidinger M, Raderer M. The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing? Ann Oncol 2002;13:653-68. [PMID: 12075733 DOI: 10.1093/annonc/mdf142] [Cited by in Crossref: 88] [Cited by in F6Publishing: 81] [Article Influence: 4.6] [Reference Citation Analysis]
22 Bousquet C, Guillermet J, Vernejoul F, Lahlou H, Buscail L, Susini C. Somatostatin receptors and regulation of cell proliferation. Dig Liver Dis. 2004;36 Suppl 1:S2-S7. [PMID: 15077905 DOI: 10.1016/j.dld.2003.11.007] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
23 Tao Y, Li M, Auguste DT. Pattern-based sensing of triple negative breast cancer cells with dual-ligand cofunctionalized gold nanoclusters. Biomaterials 2017;116:21-33. [PMID: 27914264 DOI: 10.1016/j.biomaterials.2016.11.050] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 6.6] [Reference Citation Analysis]
24 Smitha MC, Maggi M, Orlando C. Somatostatin receptors in non-endocrine tumours. Dig Liver Dis. 2004;36 Suppl 1:S78-S85. [PMID: 15077915 DOI: 10.1016/j.dld.2003.11.019] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
25 Yuan M, Wang J, Deng J, Wang Z, Yang W, Li G, Ren B. Combination therapy in A549 cells. Nuclear Medicine and Biology 2010;37:317-26. [DOI: 10.1016/j.nucmedbio.2009.11.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
26 Bajetta E, Procopio G, Ferrari L, Martinetti A, Zilembo N, Catena L, Alú M, Della TS, Alberti D, Buzzoni R. A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma. Cancer 2002;94:299-304. [PMID: 11900215 DOI: 10.1002/cncr.10239] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
27 Tang C, Liu C, Zhou X, Wang C. Enhanced inhibitive effects of combination of rofecoxib and octreotide on the growth of human gastric cancer. Int J Cancer 2004;112:470-4. [DOI: 10.1002/ijc.20256] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
28 Zupanc GK. Neurogenesis and neuronal regeneration in the adult fish brain. J Comp Physiol A Neuroethol Sens Neural Behav Physiol 2006;192:649-70. [PMID: 16463148 DOI: 10.1007/s00359-006-0104-y] [Cited by in Crossref: 133] [Cited by in F6Publishing: 121] [Article Influence: 8.9] [Reference Citation Analysis]
29 Li D, Tanaka M, Brunicardi FC, Fisher WE, Gibbs RA, Gingras MC. Association between somatostatin receptor 5 gene polymorphisms and pancreatic cancer risk and survival. Cancer 2011;117:2863-72. [PMID: 21692047 DOI: 10.1002/cncr.25858] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
30 Plonowski A, Schally AV, Letsch M, Krupa M, Hebert F, Busto R, Groot K, Varga JL. Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: Lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor. Prostate 2002;52:173-82. [DOI: 10.1002/pros.10105] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
31 Li Y, Si JM, Zhang J, Du J, Wang F, Jia B. Somatostatin receptor subtype 2-mediated scintigraphy and localization using 99mTc-HYNIC-Tyr3-octreotide in human hepatocellular carcinoma-bearing nude mice. World J Gastroenterol 2005; 11(25): 3953-3957 [PMID: 15991301 DOI: 10.3748/wjg.v11.i25.3953] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
32 Vilar L, Naves L, Freitas MDC, Oliveira Jr S, Leite V, Canadas V. Tratamento medicamentoso dos tumores hipofisários. Parte I: prolactinomas e adenomas secretores de GH. Arq Bras Endocrinol Metab 2000;44:367-81. [DOI: 10.1590/s0004-27302000000500003] [Cited by in Crossref: 6] [Article Influence: 0.3] [Reference Citation Analysis]
33 王龙, 朱金水, 陈维雄, 朱励, 达炜, 王秀玲. 奥曲肽联合汉防己甲素对人胃癌细胞增殖的影响. 世界华人消化杂志 2005; 13(19): 2318-2322 [DOI: 10.11569/wcjd.v13.i19.2318] [Reference Citation Analysis]
34 Malaguarnera M, Cristaldi E, Cammalleri L, Colonna V, Lipari H, Capici A, Cavallaro A, Beretta M, Alessandria I, Luca S, Motta M. Elevated chromogranin A (CgA) serum levels in the patients with advanced pancreatic cancer. Archives of Gerontology and Geriatrics 2009;48:213-7. [DOI: 10.1016/j.archger.2008.01.014] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
35 Jaracz S, Chen J, Kuznetsova LV, Ojima I. Recent advances in tumor-targeting anticancer drug conjugates. Bioorg Med Chem 2005;13:5043-54. [PMID: 15955702 DOI: 10.1016/j.bmc.2005.04.084] [Cited by in Crossref: 356] [Cited by in F6Publishing: 316] [Article Influence: 22.3] [Reference Citation Analysis]
36 Halmos G, Schally AV, Comaru-schally AM, Nagy A, Irimpen A. Absence of binding of targeted analogs of somatostatin carrying cytotoxic radicals or radionuclides to growth hormone secretagogue receptors on human myocardium. Life Sciences 2003;72:2669-74. [DOI: 10.1016/s0024-3205(03)00181-4] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
37 Hofsli E, Thommesen L, Nørsett K, Falkmer S, Syversen U, Sandvik A, Laegreid A. Expression of chromogranin A and somatostatin receptors in pancreatic AR42J cells. Mol Cell Endocrinol 2002;194:165-73. [PMID: 12242039 DOI: 10.1016/s0303-7207(02)00131-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
38 Guyotat J, Champier J, Jouvet A, Signorelli F, Houzard C, Bret P, Saint Pierre G, Fevre Montange M. Differential expression of somatostatin receptors in ependymoma: Implications for diagnosis. Int J Cancer 2001;95:144-51. [DOI: 10.1002/1097-0215(20010520)95:3<144::aid-ijc1025>3.0.co;2-w] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
39 Halmos G, Schally AV, Sun B, Davis R, Bostwick DG, Plonowski A. High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers. J Clin Endocrinol Metab 2000;85:2564-71. [PMID: 10902809 DOI: 10.1210/jcem.85.7.6698] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
40 Csernus VJ, Schally AV, Kiaris H, Armatis P. Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro. Proc Natl Acad Sci U S A 1999;96:3098-103. [PMID: 10077643 DOI: 10.1073/pnas.96.6.3098] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 2.5] [Reference Citation Analysis]
41 Burroughs KD, Dunn SE, Barrett JC, Taylor JA. Insulin-Like Growth Factor-I: a Key Regulator of Human Cancer Risk? JNCI Journal of the National Cancer Institute 1999;91:579-81. [DOI: 10.1093/jnci/91.7.579] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 1.7] [Reference Citation Analysis]
42 Rodon J, DeSantos V, Ferry RJ, Kurzrock R. Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol Cancer Ther. 2008;7:2575-2588. [PMID: 18790742 DOI: 10.1158/1535-7163.mct-08-0265] [Cited by in Crossref: 129] [Cited by in F6Publishing: 66] [Article Influence: 9.9] [Reference Citation Analysis]
43 Oztürk HB, Vural B, Calışkan E, Solakoğlu S. Effect of GnRH analogues and octreotide treatment on apoptosis and the cell proliferation of endometrium adenocarcinoma cell lines. J Turk Ger Gynecol Assoc 2010;11:131-6. [PMID: 24591918 DOI: 10.5152/jtgga.2010.19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
44 Guyotat J, Champier J, Pierre GS, Jouvet A, Bret P, Brisson C, Belin MF, Signorelli F, Montange MF. Differential expression of somatostatin receptors in medulloblastoma. J Neurooncol 2001;51:93-103. [PMID: 11386415 DOI: 10.1023/a:1010624702443] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
45 Lahlou H, Saint-Laurent N, Estève JP, Eychène A, Pradayrol L, Pyronnet S, Susini C. sst2 Somatostatin receptor inhibits cell proliferation through Ras-, Rap1-, and B-Raf-dependent ERK2 activation. J Biol Chem 2003;278:39356-71. [PMID: 12878607 DOI: 10.1074/jbc.M304524200] [Cited by in Crossref: 87] [Cited by in F6Publishing: 29] [Article Influence: 4.8] [Reference Citation Analysis]
46 Rochaix P, Delesque N, Estève JP, Saint-Laurent N, Voight JJ, Vaysse N, Susini C, Buscail L. Gene therapy for pancreatic carcinoma: local and distant antitumor effects after somatostatin receptor sst2 gene transfer. Hum Gene Ther 1999;10:995-1008. [PMID: 10223733 DOI: 10.1089/10430349950018391] [Cited by in Crossref: 66] [Cited by in F6Publishing: 58] [Article Influence: 3.0] [Reference Citation Analysis]
47 Martinez-Alonso M, Llecha N, Mayorga ME, Sorolla A, Dolcet X, Sanmartin V, Abal L, Casanova JM, Baradad M, Yeramian A, Egido R, Puig S, Vilella R, Matias-Guiu X, Marti RM. Expression of somatostatin receptors in human melanoma cell lines: effect of two different somatostatin analogues, octreotide and SOM230, on cell proliferation. J Int Med Res 2009;37:1813-22. [PMID: 20146879 DOI: 10.1177/147323000903700617] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
48 England R, Atkin S. Somatostatins and their role in thyroid cancer. Clin Otolaryngol 2002;27:120-3. [DOI: 10.1046/j.1365-2273.2002.00543.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
49 Zupanc GK, Clint SC. Radial glia-mediated up-regulation of somatostatin in the regenerating adult fish brain. Neuroscience Letters 2001;309:149-52. [DOI: 10.1016/s0304-3940(01)02061-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
50 Wang CH, Tang CW, Liu CL, Tang LP. Inhibitory effect of octreotide on gastric cancer growth via MAPK pathway. World J Gastroenterol 2003; 9(9): 1904-1908 [PMID: 12970873 DOI: 10.3748/wjg.v9.i9.1904] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 19] [Article Influence: 0.9] [Reference Citation Analysis]
51 Dasgupta P, Mukherjee R. Lipophilization of somatostatin analog RC-160 with long chain fatty acid improves its antiproliferative and antiangiogenic activity in vitro. Br J Pharmacol 2000;129:101-9. [PMID: 10694208 DOI: 10.1038/sj.bjp.0702990] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
52 Talme T, Ivanoff J, Sundqvist KG. Somatostatin is a specific inhibitor of SDF-1alpha-induced T cell infiltration. Clin Exp Immunol 2004;135:434-9. [PMID: 15008975 DOI: 10.1111/j.1365-2249.2003.02370.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
53 Zalatnai A. Pancreatic cancer - a continuing challenge in oncology. Pathol Oncol Res 2003;9:252-63. [PMID: 14688834 DOI: 10.1007/BF02893388] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
54 Sciarra A, Bosman C, Monti G, Gentile V, Gomez AMA, Ciccariello M, Pastore A, Salvatori G, Fattore F, Di Silverio F. SOMATOSTATIN ANALOGUES AND ESTROGENS IN THE TREATMENT OF ANDROGEN ABLATION REFRACTORY PROSTATE ADENOCARCINOMA. Journal of Urology 2004;172:1775-83. [DOI: 10.1097/01.ju.0000140875.07255.f5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
55 Appetecchia M, Baldelli R. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives. J Exp Clin Cancer Res. 2010;29:19. [PMID: 20196864 DOI: 10.1186/1756-9966-29-19] [Cited by in Crossref: 82] [Cited by in F6Publishing: 74] [Article Influence: 7.5] [Reference Citation Analysis]
56 Abdel-Hamid NM, Mohafez OM, Zakaria S, Thabet K. Hepatic somatostatin receptor 2 expression during premalignant stages of hepatocellular carcinoma. Tumour Biol 2014;35:2497-502. [PMID: 24163059 DOI: 10.1007/s13277-013-1330-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
57 Zupanc G. Adult Neurogenesis and Neuronal Regeneration in the Teleost Fish Brain: Implications for the Evolution of a Primitive Vertebrate Trait. Evolution of Nervous Systems. Elsevier; 2007. pp. 485-519. [DOI: 10.1016/b0-12-370878-8/00340-2] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
58 Kah�n Z, Nagy A, Schally AV, Hebert F, Sun B, Groot K, Halmos G. Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238. Int J Cancer 1999;82:592-8. [DOI: 10.1002/(sici)1097-0215(19990812)82:4<592::aid-ijc20>3.0.co;2-0] [Cited by in Crossref: 29] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
59 Pollak M. Insulin-like growth factor physiology and cancer risk. European Journal of Cancer 2000;36:1224-8. [DOI: 10.1016/s0959-8049(00)00102-7] [Cited by in Crossref: 189] [Cited by in F6Publishing: 56] [Article Influence: 9.0] [Reference Citation Analysis]
60 Ovadia O, Greenberg S, Laufer B, Gilon C, Hoffman A, Kessler H. Improvement of drug-like properties of peptides: the somatostatin paradigm. Expert Opinion on Drug Discovery 2010;5:655-71. [DOI: 10.1517/17460441.2010.493935] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 4.5] [Reference Citation Analysis]
61 Koutsilieris M, Tzanela M, Dimopoulos T. Novel concept of antisurvival factor (ASF) therapy produces an objective clinical response in four patients with hormone-refractory prostate cancer: Case report. Prostate 1999;38:313-6. [DOI: 10.1002/(sici)1097-0045(19990301)38:4<313::aid-pros7>3.0.co;2-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
62 Shojamanesh H, Gibril F, Louie A, Ojeaburu JV, Bashir S, Abou-Saif A, Jensen RT. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer. 2002;94:331-343. [PMID: 11900219 DOI: 10.1002/cncr.10195] [Cited by in Crossref: 155] [Cited by in F6Publishing: 121] [Article Influence: 8.2] [Reference Citation Analysis]
63 Dasgupta P. Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol Ther. 2004;102:61-85. [PMID: 15056499 DOI: 10.1016/j.pharmthera.2004.02.002] [Cited by in Crossref: 109] [Cited by in F6Publishing: 96] [Article Influence: 6.4] [Reference Citation Analysis]
64 Lindsay CR, Evans TJ. The insulin-like growth factor system and its receptors: A potential novel anticancer target. Biologics 2008;2:855-64. [PMID: 19707463 DOI: 10.2147/btt.s3841] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
65 Cattaneo MG, Taylor JE, Culler MD, Nisoli E, Vicentini LM. Selective stimulation of somatostatin receptor subtypes: differential effects on Ras/MAP kinase pathway and cell proliferation in human neuroblastoma cells. FEBS Lett 2000;481:271-6. [PMID: 11007977 DOI: 10.1016/s0014-5793(00)02012-3] [Cited by in Crossref: 40] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
66 Staykova ST, Wesselinova DW, Vezenkov LT, Naydenova ED. Synthesis and in vitro antitumor activity of new octapeptide analogs of somatostatin containing unnatural amino acids. Amino Acids 2015;47:1007-13. [DOI: 10.1007/s00726-015-1929-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
67 Zupanc GK. Up-regulation of somatostatin after lesions in the cerebellum of the teleost fish Apteronotus leptorhynchus. Neuroscience Letters 1999;268:135-8. [DOI: 10.1016/s0304-3940(99)00299-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
68 Zalatnai A, Galambos E, Perjési E. Importance of Immunohistochemical Detection of Somatostatin Receptors. Pathol Oncol Res 2019;25:521-5. [DOI: 10.1007/s12253-018-0426-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
69 Dizeyi N, Konrad L, Bjartell A, Wu H, Gadaleanu V, Hansson J, Helboe L, Abrahamsson PA. Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines. Urol Oncol 2002;7:91-8. [PMID: 12474541 DOI: 10.1016/s1078-1439(01)00173-9] [Cited by in Crossref: 37] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
70 Pfisterer A, Eisele K, Chen X, Wagner M, Müllen K, Weil T. Bioactive unnatural somatostatin analogues through bioorthogonal iodo- and ethynyl-disulfide intercalators. Chemistry 2011;17:9697-707. [PMID: 21748812 DOI: 10.1002/chem.201100287] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
71 Jaber S, Iliev I, Angelova T, Nemska V, Sulikovska I, Naydenova E, Georgieva N, Givechev I, Grabchev I, Danalev D. Synthesis, Antitumor and Antibacterial Studies of New Shortened Analogues of (KLAKLAK)2-NH2 and Their Conjugates Containing Unnatural Amino Acids. Molecules 2021;26:898. [PMID: 33567789 DOI: 10.3390/molecules26040898] [Reference Citation Analysis]
72 Dubey N, Varshney R, Shukla J, Ganeshpurkar A, Hazari PP, Bandopadhaya GP, Mishra AK, Trivedi P. Synthesis and evaluation of biodegradable PCL/PEG nanoparticles for neuroendocrine tumor targeted delivery of somatostatin analog. Drug Deliv 2012;19:132-42. [PMID: 22428685 DOI: 10.3109/10717544.2012.657718] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
73 Nagy A, Schally AV, Halmos G, Armatis P, Cai RZ, Csernus V, Kovács M, Koppán M, Szepesházi K, Kahán Z. Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. Proc Natl Acad Sci U S A 1998;95:1794-9. [PMID: 9465096 DOI: 10.1073/pnas.95.4.1794] [Cited by in Crossref: 101] [Cited by in F6Publishing: 93] [Article Influence: 4.4] [Reference Citation Analysis]
74 Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000;21:215-44. [PMID: 10857553 DOI: 10.1210/edrv.21.3.0399] [Cited by in Crossref: 382] [Cited by in F6Publishing: 397] [Article Influence: 18.2] [Reference Citation Analysis]
75 Deghenghi R. Synthetic peptides and their non-peptidyl mimetics in endocrinology: from synthesis to clinical perspectives. J Endocrinol Invest 1998;21:787-93. [PMID: 9972682 DOI: 10.1007/BF03348048] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
76 Talme T, Ivanoff J, Hägglund M, Van Neerven RJ, Ivanoff A, Sundqvist KG. Somatostatin receptor (SSTR) expression and function in normal and leukaemic T-cells. Evidence for selective effects on adhesion to extracellular matrix components via SSTR2 and/or 3. Clin Exp Immunol 2001;125:71-9. [PMID: 11472428 DOI: 10.1046/j.1365-2249.2001.01577.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 1.2] [Reference Citation Analysis]
77 Wang JH, Xing QT, Yuan MB. Antineoplastic effects of octreotide on human gallbladder cancer cells in vitroWorld J Gastroenterol 2004; 10(7): 1043-1046 [PMID: 15052690 DOI: 10.3748/wjg.v10.i7.1043] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
78 Patel P, Galoian K. Molecular challenges of neuroendocrine tumors. Oncol Lett. 2018;15:2715-2725. [PMID: 29456718 DOI: 10.3892/ol.2017.7680] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
79 Lawnicka H, Stepień H, Wyczółkowska J, Kolago B, Kunert-Radek J, Komorowski J. Effect of somatostatin and octreotide on proliferation and vascular endothelial growth factor secretion from murine endothelial cell line (HECa10) culture. Biochem Biophys Res Commun 2000;268:567-71. [PMID: 10679244 DOI: 10.1006/bbrc.2000.2119] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 1.5] [Reference Citation Analysis]
80 Szepeshazi K, Schally AV, Groot K, Armatis P, Halmos G, Herbert F, Szende B, Varga JL, Zarandi M. Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers. Br J Cancer 2000;82:1724-31. [PMID: 10817510 DOI: 10.1054/bjoc.2000.1223] [Cited by in Crossref: 23] [Cited by in F6Publishing: 29] [Article Influence: 1.1] [Reference Citation Analysis]
81 Engel JB, Schally AV, Halmos G, Baker B, Nagy A, Keller G. Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1. Cancer 2005;104:1312-21. [DOI: 10.1002/cncr.21327] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
82 Baldelli R, Barnabei A, Rizza L, Isidori AM, Rota F, Di Giacinto P, Paoloni A, Torino F, Corsello SM, Lenzi A, Appetecchia M. Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives. Front Endocrinol (Lausanne). 2014;5:7. [PMID: 24570674 DOI: 10.3389/fendo.2014.00007] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
83 Yakar S, Leroith D, Brodt P. The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: Lessons from animal models. Cytokine Growth Factor Rev. 2005;16:407-420. [PMID: 15886048 DOI: 10.1016/j.cytogfr.2005.01.010] [Cited by in Crossref: 145] [Cited by in F6Publishing: 117] [Article Influence: 9.1] [Reference Citation Analysis]
84 Naydenova E, Wesselinova D, Staykova S, Danalev D, Dzimbova T. Synthesis, in vitro biological activity and docking of new analogs of BIM-23052 containing unnatural amino acids. Amino Acids 2019;51:1247-57. [PMID: 31350614 DOI: 10.1007/s00726-019-02758-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 O'Byrne KJ, Dobbs N, Propper DJ, Braybrooke JP, Koukourakis MI, Mitchell K, Woodhull J, Talbot DC, Schally AV, Harris AL. Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer. Br J Cancer 1999;79:1413-8. [PMID: 10188884 DOI: 10.1038/sj.bjc.6690226] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.0] [Reference Citation Analysis]
86 Benali N, Cordelier P, Calise D, Pages P, Rochaix P, Nagy A, Esteve JP, Pour PM, Schally AV, Vaysse N. Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238. Proc Natl Acad Sci USA. 2000;97:9180-9185. [PMID: 10900262 DOI: 10.1073/pnas.130196697] [Cited by in Crossref: 77] [Cited by in F6Publishing: 67] [Article Influence: 3.7] [Reference Citation Analysis]
87 Mahipal A, Shibata D, Siegel E, Springett G, Almhanna K, Fulp W, Williams-Elson I, Kim R. Phase I trial of combination of FOLFIRI and pasireotide, a somatostatin analogue, in advanced gastrointestinal malignancies. Invest New Drugs 2015;33:1093-9. [PMID: 26275531 DOI: 10.1007/s10637-015-0277-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
88 Ingle JN, Suman VJ, Kardinal CG, Krook JE, Mailliard JA, Veeder MH, Loprinzi CL, Dalton RJ, Hartmann LC, Conover CA, Pollak MN. A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma. Cancer 1999;85:1284-92. [PMID: 10189133 DOI: 10.1002/(sici)1097-0142(19990315)85:6<1284::aid-cncr10>3.0.co;2-p] [Cited by in Crossref: 42] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
89 Msaouel P, Galanis E, Koutsilieris M. Somatostatin and somatostatin receptors: implications for neoplastic growth and cancer biology. Expert Opin Investig Drugs 2009;18:1297-316. [PMID: 19678799 DOI: 10.1517/13543780903176399] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
90 Alberti C, Tizzani A, Greco A, Piovano M. Neuroendocrine Differentiation in Prostatic Malignancy. Urologia 2004;71:93-103. [DOI: 10.1177/039156030407100202] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
91 Charland S, Boucher MJ, Houde M, Rivard N. Somatostatin inhibits Akt phosphorylation and cell cycle entry, but not p42/p44 mitogen-activated protein (MAP) kinase activation in normal and tumoral pancreatic acinar cells. Endocrinology. 2001;142:121-128. [PMID: 11145574 DOI: 10.1210/endo.142.1.7908] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 1.2] [Reference Citation Analysis]
92 Rahmi G, Malka D, Tomasic G, Dromain C, Ducreux M, Boige V. Complete, Long-Standing Regression of Hepatocellular Carcinoma After Somatostatin Analogue Treatment. JCO 2007;25:e15-6. [DOI: 10.1200/jco.2006.09.5760] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
93 Han SK, Kim RS, Lee JH, Tae G, Cho SH, Yuk SH. Core-Shell Nanoparticles for Drug Delivery and Molecular Imaging. In: Kumar CSSR, editor. Nanotechnologies for the Life Sciences. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA; 2007. [DOI: 10.1002/9783527610419.ntls0110] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
94 Bjellerup P, Theodorsson E, Jörnvall H, Kogner P. Limited neuropeptide Y precursor processing in unfavourable metastatic neuroblastoma tumours. Br J Cancer 2000;83:171-6. [PMID: 10901366 DOI: 10.1054/bjoc.2000.1234] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
95 Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer. 2004;4:505-518. [PMID: 15229476 DOI: 10.1038/nrc1387] [Cited by in Crossref: 975] [Cited by in F6Publishing: 850] [Article Influence: 57.4] [Reference Citation Analysis]
96 Marek B, Kajdaniuk D, Kos-kudła B, Ostrowska Z, Niedziołka D, Janczewska-kazek E. Acromegaly and the risk of cancer. Pathophysiology 2001;8:69-75. [DOI: 10.1016/s0928-4680(01)00078-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
97 González-Barcena D, Schally AV, Vadillo-Buenfil M, Cortez-Morales A, Hernández L V, Cardenas-Cornejo I, Comaru-Schally AM. Response of patients with advanced prostatic cancer to administration of somatostatin analog RC-160 (vapreotide) at the time of relapse. Prostate. 2003;56:183-191. [PMID: 12772187 DOI: 10.1002/pros.10232] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.0] [Reference Citation Analysis]
98 Debruyne F, Bhat G, Garnick MB. Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer. Future Oncology 2006;2:677-96. [DOI: 10.2217/14796694.2.6.677] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
99 Szepeshazi K, Schally AV, Nagy A, Wagner BW, Bajo AM, Halmos G. Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas. Cancer. 2003;98:1401-1410. [PMID: 14508826 DOI: 10.1002/cncr.11649] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 1.7] [Reference Citation Analysis]
100 Giovannucci E, Pollak M. Risk of cancer after growth-hormone treatment. The Lancet 2002;360:268-9. [DOI: 10.1016/s0140-6736(02)09561-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
101 Guarnotta V, Martini C, Davì MV, Pizza G, Colao A, Faggiano A; NIKE group. The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma?Endocrine. 2018;60:15-27. [PMID: 29019150 DOI: 10.1007/s12020-017-1420-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
102 Torrisani J, Bouisson M, Puente E, Capella G, Laurent-Puig P, Berger A, Vaysse N, Susini C, Buscail L. Transcription of SST2 somatostatin receptor gene in human pancreatic cancer cells is altered by single nucleotide promoter polymorphism. Gastroenterology. 2001;120:200-209. [PMID: 11208729 DOI: 10.1053/gast.2001.21192] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
103 Dalezis P, Trafalis DT, Geromichalos GD, Pissimissis N, Panagiotopoulou D, Galaktidou G, Papageorgiou E, Papageorgiou A, Lymperi M, Koutsilieris M. Adriamycin in combination with dexamethasone and octreotide lacks activity on the treatment of a 4T1 metastatic breast cancer model. Anticancer Drugs 2017;28:489-502. [PMID: 28272098 DOI: 10.1097/CAD.0000000000000484] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
104 Kvols LK, Woltering EA. Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumors. Anticancer Drugs 2006;17:601-8. [PMID: 16917205 DOI: 10.1097/01.cad.0000210335.95828.ed] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
105 Ye Q, Asherman J, Stevenson M, Brownson E, Katre NV. DepoFoam™ technology: a vehicle for controlled delivery of protein and peptide drugs. Journal of Controlled Release 2000;64:155-66. [DOI: 10.1016/s0168-3659(99)00146-7] [Cited by in Crossref: 88] [Cited by in F6Publishing: 11] [Article Influence: 4.2] [Reference Citation Analysis]
106 Milewicz T, Kolodziejczyk J, Krzysiek J, Basta A, Sztefko K, Kurek S, Stachura J, Gregoraszczuk EL. Cyproterone, norethindrone, medroxyprogesterone and levonorgestrel are less potent local human growth hormone and insulin-like growth factor I secretion stimulators than progesterone in human breast cancer explants expressing the estrogen receptor. Gynecological Endocrinology 2009;16:319-29. [DOI: 10.1080/gye.16.4.319.329] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
107 Huang M, Chen Z, Wei B, Zhang B, Wang C, Huang M, Liu R, Tang C. Preoperative growth inhibition of human gastric adenocarcinoma treated with a combination of celecoxib and octreotide. Acta Pharmacol Sin 2007;28:1842-50. [DOI: 10.1111/j.1745-7254.2007.00652.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
108 Ferone D, Hofland LJ, Colao A, Lamberts SW, van Hagen PM. Neuroendocrine aspects of immunolymphoproliferative diseases. Ann Oncol 2001;12 Suppl 2:S125-30. [PMID: 11762338 DOI: 10.1093/annonc/12.suppl_2.s125] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
109 Petrucci C, Cervia D, Buzzi M, Biondi C, Bagnoli P. Somatostatin-induced control of cytosolic free calcium in pituitary tumour cells. Br J Pharmacol. 2000;129:471-484. [PMID: 10711345 DOI: 10.1038/sj.bjp.0703075] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 1.2] [Reference Citation Analysis]
110 Spieth ME, Lin YG, Nguyen TT. Diagnosing and treating small-cell carcinomas of prostatic origin. Clin Nucl Med 2002;27:11-7. [PMID: 11805477 DOI: 10.1097/00003072-200201000-00003] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
111 Schally AV, Comaru-Schally AM, Nagy A, Kovacs M, Szepeshazi K, Plonowski A, Varga JL, Halmos G. Hypothalamic hormones and cancer. Front Neuroendocrinol. 2001;22:248-291. [PMID: 11587553 DOI: 10.1006/frne.2001.0217] [Cited by in Crossref: 193] [Cited by in F6Publishing: 181] [Article Influence: 9.7] [Reference Citation Analysis]
112 Jonmarker S, Glaessgen A, Culp WD, Pisa P, Lewensohn R, Ekman P, Valdman A, Egevad L. Expression of PDX-1 in prostate cancer, prostatic intraepithelial neoplasia and benign prostatic tissue. APMIS 2008;116:491-8. [PMID: 18754323 DOI: 10.1111/j.1600-0463.2008.01020.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]